BOT501 is a PDGF-ß-receptor targeted radionuclide-bicyclic peptide conjugate.
Accumulation of BOT501 in PDGF-ß-receptor overexpressing cells has demonstrated to be disease-specific with functional signal/background ratios in heart, liver, lungs and kidneys.
In the imaging diagnostic BOT501-i, a PET radionuclide, 68Gallium, is conjugated to the PDGF-ß-receptor binding bicyclic peptide. Conjugation procedures differ, appropriate for its specific application in a fibrotic liver or fibrotic stroma in cancer. Further, dependent on the accumulation rate of the PET radionuclide-peptide complex and the background clearance rate in a fibrotic organ, the selected PET radionuclide can be 68Gallium, 18Fluorin or 111Indium.
In BOT501-t, the RadioLigand Therapeutic version, 177Lutetium is conjugated to the PDGF-ß-receptor binding bicyclic peptide. This radiotherapeutic will be developed to treat patients with advanced and metastasized CMS4 subtype colon cancer.